589 reports of this reaction
1.1% of all MINOCYCLINE reports
#20 most reported adverse reaction
C REACTIVE PROTEIN INCREASED is the #20 most commonly reported adverse reaction for MINOCYCLINE, manufactured by Journey Medical Corporation. There are 589 FDA adverse event reports linking MINOCYCLINE to C REACTIVE PROTEIN INCREASED. This represents approximately 1.1% of all 54,303 adverse event reports for this drug.
Patients taking MINOCYCLINE who experience c reactive protein increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
C REACTIVE PROTEIN INCREASED is a less commonly reported adverse event for MINOCYCLINE, but still significant enough to appear in the safety profile.
In addition to c reactive protein increased, the following adverse reactions have been reported for MINOCYCLINE:
The following drugs have also been linked to c reactive protein increased in FDA adverse event reports:
C REACTIVE PROTEIN INCREASED has been reported as an adverse event in 589 FDA reports for MINOCYCLINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
C REACTIVE PROTEIN INCREASED accounts for approximately 1.1% of all adverse event reports for MINOCYCLINE, making it a notable side effect.
If you experience c reactive protein increased while taking MINOCYCLINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.